Skip to Main Content

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Conditions

Diseases of the Digestive System - Small Intestines, Large Intestines & Rectum

Phase III

What is the purpose of this trial?

Brief Summary:

This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.

  • Trial with
    Celgene Corporation
  • Start Date
    05/13/2019
  • End Date
    01/30/2021
Trial Image

For more information about this study, contact:

Elizabeth Ruggiero

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/07/2019
  • Study HIC
    #2000024497